Skip to main content

Table 1 Basic information of the eligible articles in the meta-analysis

From: Glutathione S-transferase pi 1 variant and squamous cell carcinoma susceptibility: a meta-analysis of 52 case-control studies

First author Year Region Race Assay Case Disease type Control Control source P HWE
AA AG GG AA AG GG
Abbas 2004 France Caucasian PCR-RFLP 21 21 3 ESCC 59 56 9 PB 0.38
Cabelguenne 2001 France Caucasian PCR-RFLP 89 57 16 HNSCC 146 139 25 HB 0.31
Cai 2006 China Asian PCR-RFLP 143 58 3 ESCC 265 116 12 PB 0.87
Cho 2006 Korea Asian Gene sequencing 201 85 7 HNSCC 211 112 10 HB 0.29
Dura 2013 Netherlands Caucasian PCR 48 42 15 ESCC 246 261 84 PB 0.27
Dzian 2012 Netherlands Caucasian PCR-RFLP 56 45 11 LSCC 153 115 22 PB/HB 0.95
Evans 2004 USA Caucasian PCR-RFLP 123 132 27 HNSCC 97 85 24 PB 0.42
Fryer 2005 Australia Caucasian PCR-RFLP 59 51 18 SSCC 95 90 25 HB 0.60
Harth 2008 Germany Caucasian PCR-melting-curve 145 122 45 HNSCC 130 138 32 HB 0.62
Jain 2006 India Asian PCR-RFLP 46 23 7 ESCC 72 56 9 HB 0.67
Jourenkova 1999a France Caucasian PCR-RFLP 49 53 15 HNSCC 86 64 22 HB 0.07
Jourenkova 1999b France Caucasian PCR-RFLP 62 52 15 HNSCC 86 64 22 HB 0.07
Jourenkova 1998 France Caucasian PCR-RFLP 46 41 11 LSCC 86 64 22 HB 0.07
Kelders 2002 Netherlands Caucasian PCR-RFLP 36 38 13 HNSCC 26 18 7 HB 0.20
Kihara 1999 Japan Asian PCR-RFLP 84 32 9 LSCC 184 65 8 HB 0.45
Larsen 2006 Australia Caucasian PCR-RFLP 230 213 51 LSCC 161 169 49a HB 0.66
   Australia Caucasian PCR-RFLP 230 213 51 LSCC 112 100 35b PB 0.11
Leichsenring 2006 Brazil Mixed PCR-RFLP 30 34 8 HNSCC 30 25 5 PB 0.95
Leite 2007 Brazil Mixed PCR-RFLP 14 13 2 SSCC 60 46 18 PB 0.07
Lewis 2002 UK Caucasian PCR-RFLP 14 17 1 LSCC 64 74 13 HB 0.19
Li 2010 South African Black African PCR-RFLP 56 59 26 ESCC 76 83 27 PB 0.58
    Mixed PCR-RFLP 34 52 11 ESCC 30 51 13 PB 0.24
Li 2007 USA Caucasian PCR-RFLP 336 356 111 HNSCC 333 385 121 PB 0.57
Liang 2005 China Asian diASA-AMP 58 32 4 LSCC 132 86 9 HB 0.27
Liu 2010 China Asian PCR-RFLP 66 29 0 ESCC 61 27 3 PB 1.00
Malik 2010 India Asian PCR-RFLP 53 36 14 ESCC 111 75 9 PB 0.41
Matejcic 2011 South African Black African TaqMan genotyping 79 155 91 ESCC 100 242 132 PB 0.57
   South African Mixed TaqMan genotyping 69 112 48 ESCC 145 191 92 PB 0.05
McWilliams 2000 USA Mixed PCR-RFLP 60 73 13 HNSCC 58 51 15 HB 0.47
Miller 2006 USA Caucasian PCR-RFLP 190 173 49 LSCC 579 623 141 PB 0.16
Moaven 2010 Iran Asian PCR-RFLP 84 50 14 ESCC 74 54 8 PB 0.65
Nazar 2003 USA Mixed PCR-RFLP 35 29 9 LSCC 199 234 54 PB 0.23
Olshan 2000 USA Mixed PCR-RFLP 40 62 7 HNSCC 68 80 20 HBc 0.63
   USA Mixed PCR-RFLP 18 38 7 HNSCC 7 13 5 HBd 0.82
Oude 2003 Netherlands Caucasian PCR-RFLP 116 90 29 HNSCC 125 121 39 PB 0.27
Peters 2006 USA Mixed PCR-RFLP 303 311 76 HNSCC 333 329 86 PB 0.73
Ramsay 2001 UK Caucasian SSCP 10 10 0 SSCC 53 71 17 HB 0.36
Risch 2001 Germany Caucasian PCR-RFLP 76 77 18 LSCC 167 151 35 HB 0.92
Rossini 2007 Brazil Mixed PCR-RFLP 42 65 18 ESCC 116 108 28 PB 0.71
Ruwali 2009 India Caucasian PCR-RFLP 224 112 14 HNSCC 199 138 13 PB 0.06
Ruwali 2011 India Caucasian PCR-RFLP 316 162 22 HNSCC 285 195 20 PB 0.06
Ryberg 1997 Norway Caucasian PCR-RFLP 20 34 13 LSCC 153 117 27 PB 0.50
Schneider 2004 Germany Caucasian PCR-melting-curve 81 75 27 LSCC 298 254 70 PB/HB 0.16
Soucek 2010 Czech/Polish Caucasian TaqMan drug metabolism genotyping 56 53 7 HNSCC 57 50 10 PB 0.52
Soya 2007 India Asian PCR-RFLP 219 162 27 UADTSCC 120 88 12 PB 0.42
Stücker 2002 France Caucasian PCR-RFLP 54 46 15 LSCC 124 120 20 HB 0.22
Tan 2000 China Asian PCR-RFLP 93 48 9 ESCC 91 53 6 PB 0.62
To 2002 Spain Caucasian PCR-RFLP 101 84 19 HNSCC 100 78 23 PB 0.20
To 1999 Spain Caucasian PCR-RFLP 29 20 3 LSCC 64 54 14 PBb 0.61
   Spain Caucasian PCR-RFLP 29 20 3 LSCC 90 90 20 PBe 0.72
van 1999 Netherlands Caucasian PCR-RFLP 5 6 2 ESCC 146 89 12 PB 0.74
Zendehdel 2009 Sweden Caucasian Pyrosequencing 26 42 10 ESCC 208 207 38 PB 0.18
  1. PCR polymerase chain reaction, PCR-RFLP polymerase chain reaction-restriction fragment length polymorphism, diASA-AMP di-allele-specific-amplification with artificially modified primers assay, SSCP Single-stranded conformational polymorphism, ESCC oesophageal squamous cell carcinoma, HNSCC head and neck squamous cell carcinoma, LSCC lung squamous cell carcinoma, SSCC skin squamous cell carcinoma, OSCC oral squamous cell carcinoma, UADTSCC upper aerodigestive tract squamous cell carcinoma, PB population-based, HB hospital-based, PHWE P value of hardy-weinberg equilibrium
  2. aCOPD patients without LSCC, bhealthy smokers; ccontrol from Caucasian population; dcontrol from Black African population; econtrol from general population